P3-14-15: Non-Randomized, Open Label Phase II Trial Evaluating the Safety and Efficacy of Taxotere (T) Followed by Myocet (M) + Cyclophosphamide (C) as First-Line Treatment for HER2−Negative Breast Cancer (BC).

Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial

Haematologica ◽

10.3324/haematol.2019.220301 ◽

2019 ◽

Vol 105 (1) ◽

pp. e29-e32 ◽

Cited By ~ 2

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Hemophagocytic Lymphohistiocytosis ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Non Hodgkin Lymphoma ◽

Open Label Phase ◽

Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial

ESMO Open ◽

10.1016/j.esmoop.2021.100313 ◽

2021 ◽

Vol 6 (6) ◽

pp. 100313

Author(s):

T. Zhou ◽

Y. Yang ◽

S. Ma ◽

L. Lin ◽

T. Zhou ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Metastatic Nasopharyngeal Carcinoma ◽

Open Label Phase ◽

SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results.

10.1158/0008-5472.sabcs-3126 ◽

2009 ◽

Cited By ~ 3

Author(s):

E Mayer ◽

M Kozloff ◽

R Qamar ◽

B Klencke ◽

J Balkissoon ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Safety And Efficacy ◽

Randomized Phase Ii ◽

P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.

10.1158/0008-5472.sabcs11-p1-17-01 ◽

2011 ◽

Cited By ~ 4

Author(s):

PD Ryan ◽

P Neven ◽

KL Blackwell ◽

LY Dirix ◽

CH Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Hormone Receptor Positive ◽

Open Label Phase ◽

SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz100.047 ◽

2019 ◽

Vol 30 ◽

pp. iii63

Author(s):

V. Boni ◽

C. Alemany ◽

J.L. Meisel ◽

R. Sinha ◽

D. Sterrenberg ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Ib ◽

Open Label Phase ◽

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Investigational New Drugs ◽

10.1007/s10637-018-0599-4 ◽

2018 ◽

Vol 36 (4) ◽

pp. 674-682 ◽

Cited By ~ 1

Author(s):

Arthur Lui ◽

Karen Mulder ◽

Christine Brezden-Masley ◽

Michael Vickers ◽

Jose Monzon ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase II Trial with Gemcitabine, Paclitaxel and Bevacizumab for the First Line Treatment of Metastatic Breast Cancer.

10.1158/0008-5472.sabcs-09-6089 ◽

2009 ◽

Cited By ~ 2

Author(s):

A. Guardino ◽

M. Chen ◽

M. Levy ◽

C. Chen

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.

10.1158/0008-5472.sabcs11-p5-19-03 ◽

2011 ◽

Cited By ~ 1

Author(s):

WJ Gradishar ◽

D Krasnojon ◽

S Cheporov ◽

AN Makhson ◽

GM Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Abstract P5-17-05: Sorafenib plus Ixabepilone as First-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer: Preliminary Results of the Phase II Trial of the Sarah Cannon Research Institute

10.1158/0008-5472.sabcs12-p5-17-05 ◽

2012 ◽

Author(s):

DA Yardley ◽

J Barton ◽

N Dickson ◽

D Shipley ◽

DR Drosick ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Preliminary Results ◽

First Line Treatment ◽

Research Institute

Abstract A75: The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomized, open label Phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer.

10.1158/1535-7163.targ-13-a75 ◽

2013 ◽

Author(s):

Lorraine Chantrill ◽

Amber Johns ◽

Adnan Nagrial ◽

Venessa Chin ◽

Angela Chou ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii Trial ◽

Molecular Signature ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Pancreatic Cancer Therapy ◽

The Impact ◽